Investor Relations

Investor Search

Entire IR Site
Press Releases Only
Filings Only
Email pagePDF viewPrint viewEmail AlertRSS FeedsTearsheetMobile IR SiteSocial Media Sharing

Press Releases


Display:

Year:
Notify me when new press releases are posted to this site .
Press Releases 
DateHeadlineFormat
6/22/2012Repligen Receives Complete Response Letter from FDA for RG1068 NDA
5/30/2012Repligen to Present at Jefferies 2012 Global Healthcare Conference
5/07/2012Repligen Announces Support of Amended Stockholder Proposal
5/03/2012Repligen Reports First Quarter 2012 Financial Results
4/30/2012Repligen Announces Conference Call to Report First Quarter of 2012 Financial Results
4/26/2012Repligen Provides Regulatory Update for RG1068 New Drug Application; FDA Cancels Advisory Committee Meeting
4/25/2012Repligen Reports Positive Results from Phase 1 Clinical Trial of RG3039 for Spinal Muscular Atrophy
4/11/2012Michael A. Griffith Appointed to Repligen Board of Directors
3/23/2012Repligen Announces FDA Advisory Committee Date for SecreFlo™ NDA
3/16/2012Repligen Reports Financial Results for the Quarter and Nine-Month Fiscal Year Ended December 31, 2011
3/15/2012Repligen Initiates Phase 1 Clinical Trial of RG2833 in Patients with Friedreich’s Ataxia
3/05/2012Repligen Announces Submission of Marketing Authorization Application in EU for SecreFlo(TM) to Improve Pancreatic Imaging in Patients with Pancreatitis
2/29/2012Repligen to Present at Cowen and Company Health Care Conference
2/21/2012Repligen Announces FDA Grant of Priority Review for SecreFlo™ NDA
2/21/2012Repligen Reports Preliminary Financial Results for the Quarter and Nine-Month Fiscal Period Ended December 31, 2011
2/07/2012Repligen Launches New Products in OPUS™ Line of Pre-Packed Chromatography Columns
2/07/2012Repligen to Present at BIO CEO & Investor Conference
12/27/2011Repligen Reports Second Quarter Fiscal Year 2012 Financial Results Achieves Record Bioprocessing Product Sales
12/21/2011Repligen Announces Submission of New Drug Application for SecreFlo™ for Improved Pancreatic Imaging In Patients with Pancreatitis
12/20/2011Repligen Completes Acquisition of Novozymes Biopharma Sweden AB
Click the link to the right to download: Adobe Acrobat
 
 Source: SNL Financial LC
Rows 41 through 60 of 148 1 2 3 4 5 6 7 8

Copyright 2014, © SNL Financial LC  Terms of Use